142 related articles for article (PubMed ID: 6185132)
1. Evaluation of serum beta 2-microglobulin as a prognostic indicator in myelomatosis.
Child JA; Crawford SM; Norfolk DR; O'Quigley J; Scarffe JH; Struthers LP
Br J Cancer; 1983 Jan; 47(1):111-4. PubMed ID: 6185132
[TBL] [Abstract][Full Text] [Related]
2. Serum beta 2-microglobulin in myelomatosis: potential value in stratification and monitoring.
Norfolk D; Child JA; Cooper EH; Kerruish S; Ward AM
Br J Cancer; 1980 Oct; 42(4):510-5. PubMed ID: 6159910
[TBL] [Abstract][Full Text] [Related]
3. Serum beta 2-microglobulin: a real improvement in the management of multiple myeloma?
van Dobbenburgh OA; Rodenhuis S; Ockhuizen T; Weltevreden E; Houwen B; Fidler V; Meijer S; Marrink J
Br J Haematol; 1985 Dec; 61(4):611-20. PubMed ID: 3910076
[TBL] [Abstract][Full Text] [Related]
4. [Serum beta-2-microglobulin in multiple myeloma. Practical value].
Bataille R; Magub M; Sany J; Donadio D; Izarn P; Grenier J; Suquet P
Rev Rhum Mal Osteoartic; 1981 Mar; 48(3):235-40. PubMed ID: 6164091
[TBL] [Abstract][Full Text] [Related]
5. Serum beta-2-microglobulin in multiple myeloma: relation to presenting features and clinical status.
Bataille R; Magub M; Grenier J; Donnadio D; Sany J
Eur J Cancer Clin Oncol; 1982 Jan; 18(1):59-66. PubMed ID: 6177535
[TBL] [Abstract][Full Text] [Related]
6. [Value of the determination of beta-2-microglobulin in the monitoring of myeloma. Apropos of 290 determinations].
Kaltwasser P; Sauger F; Le Loet X; Pasquis P; Monconduit M; Deshayes P
Rev Rhum Mal Osteoartic; 1982 Apr; 49(5):359-63. PubMed ID: 6179150
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis.
Cuzick J; Cooper EH; MacLennan IC
Br J Cancer; 1985 Jul; 52(1):1-6. PubMed ID: 3893505
[TBL] [Abstract][Full Text] [Related]
8. [Serum beta 2-microglobulin in multiple myeloma. I. Relation to selected indicators, clinical stage and disease prognosis].
Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V
Vnitr Lek; 1991 Apr; 37(4):342-51. PubMed ID: 2053304
[TBL] [Abstract][Full Text] [Related]
9. Urinary excretion of beta 2-microglobulin in myeloma patients.
Engström W; Hyldahl L; Wahrgren P
Clin Chim Acta; 1980 Dec; 108(3):369-74. PubMed ID: 6162592
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system.
Bataille R; Boccadoro M; Klein B; Durie B; Pileri A
Blood; 1992 Aug; 80(3):733-7. PubMed ID: 1638024
[TBL] [Abstract][Full Text] [Related]
12. Beta 2 microglobulin in multiple myeloma.
Alexanian R; Barlogie B; Fritsche H
Am J Hematol; 1985 Dec; 20(4):345-51. PubMed ID: 3907332
[TBL] [Abstract][Full Text] [Related]
13. [Carcino-embryonic antigen and beta 2 microglobulin in malignant bone diseases. 61 cases (author's transl)].
Trèves R; Clément A; Desproges-Gotteron R; Olivier JP; Beck C
Nouv Presse Med; 1982 Jan; 11(1):21-4. PubMed ID: 6173840
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and staging in multiple myeloma: a reappraisal.
Bataille R; Durie BG; Grenier J; Sany J
J Clin Oncol; 1986 Jan; 4(1):80-7. PubMed ID: 3510284
[TBL] [Abstract][Full Text] [Related]
15. Long-term prognostic value of serum beta 2 microglobulin in myelomatosis.
Cuzick J; De Stavola BL; Cooper EH; Chapman C; MacLennan IC
Br J Haematol; 1990 Aug; 75(4):506-10. PubMed ID: 2119793
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of pretreatment serum beta 2-microglobulin levels in multiple myeloma.
Scarffe JH; Anderson H; Palmer MK; Crowther D
Eur J Cancer Clin Oncol; 1983 Oct; 19(10):1361-4. PubMed ID: 6357802
[TBL] [Abstract][Full Text] [Related]
17. [Is the serum level of beta 2 microglobulin a better marker of glomerular filtration than blood creatinine?].
François B; Assenat H; Cahen R; Bizollon C
Nephrologie; 1982; 3(3):116-8. PubMed ID: 6183598
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic implications of myeloma staging.
Durie BG; Bataille R
Eur J Haematol Suppl; 1989; 51():111-6. PubMed ID: 2697583
[TBL] [Abstract][Full Text] [Related]
19. [Clinical studies on serum beta2-microglobulin in multiple myeloma and other related diseases (author's transl)].
Nishioka F; Yachi A; Wada T
Rinsho Ketsueki; 1978 Feb; 19(2):100-6. PubMed ID: 77342
[No Abstract] [Full Text] [Related]
20. Clinical significance of correction of serum beta 2-microglobulin levels for serum creatinine in multiple myeloma.
Scudla V; Vavrdová V; Budíková M; Indrák K
Acta Univ Palacki Olomuc Fac Med; 1991; 131():257-64. PubMed ID: 1840347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
